 Genflow Biosciences PLC will become the first longevity-focused biotech ever to float in Europe when joins the London Stock Exchanges standard list. An oversubscribed placing of shares has raised 3.7mln and ascribed an initial valuation of 23.4mln to the fledgling business. 